Akcea and Ionis Announce EU Approval of Tegsedi - PharmaLive (press release)

 
 
Akcea and Ionis Announce EU Approval of TegsediPharmaLive (press release)Written by: GlobeNewswire | support@globenewswire.com | Dated: Wednesday, July 11th, 2018. Akcea and Ionis Announce Approval of TEGSEDI? (inotersen) in the European Union. CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBEá...and moreá╗
 
Related NewsFeeds

Business Wire (press release)Preparing Health Network CEOs for Success with Precision Medicine: Early-Adopter Health Systems to Gather in ...Business Wire (press release)... Julie A Johnson, PharmD, D

9 visits

Seeking Alpha3 Things In Biotech, August 14: Is Stemline Finally A Go In Cancer?Seeking AlphaWelcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to hel

11 visits

In-PharmaTechnologist.comLexaira Bioscience demonstrates high bioavailability in CBD platformIn-PharmaTechnologist.comLexaira Bioscience says its DehydraTECH platform has demonstrated significant impr

8 visits

Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence StudyNasdaqNORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

2 visits

In-PharmaTechnologist.comAnti-counterfeiting hologram tech 'only visible to informed experts', says MediPharmIn-PharmaTechnologist.comWhen opened, the seal displays an irreversible holographic

2 visits

China Biologic Products Inc Risk Points versus Health CareCML NewsIn the "Why This Matters" section at the end of this article on China Biologic Products Inc (NSDQ:CBPO) , we're going to take a st

1 visits

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q2 2018 Results - Earnings Call TranscriptSeeking AlphaSyros Pharmaceuticals. (NASDAQ:SYRS) Q2 2018 Results Earnings Conference Call August 7, 2018 8

0 visits

Weekly ObserverThe Toll of DiabetesAmerican Council on Science and HealthAs a vascular surgeon many of my patients had diabetes and in evaluating their surgical risk I was taught a rough rule of thumb

0 visits

Health24Working overtime could raise women's diabetes riskHealth24New research suggests that women who clock 45 or more hours a week have a higher risk of type 2 diabetes than women who log 35 to

13 visits

firstpharmacist.comGlobal Biologic Therapeutics Drugs Market Outlook, Size, Status, and Forecast to 2025firstpharmacist.comQYResearch.us presents a new market intelligence report on title "Global Biol

0 visits

Xeris Pharmaceuticals' $98.3 Million Initial Public OfferingGlobal Legal Chronicle (press release)Xeris Pharmaceuticals ("XERS?), a specialty pharmaceutical company leveraging its novel technology

1 visits

Pharmaceutical Business ReviewAralez Pharmaceuticals agrees to sell main operating businessesPharmaceutical Business ReviewCanadian specialty pharmaceutical firm Aralez Pharmaceuticals has entered int

4 visits

Pharmaceutical Business ReviewIzana begins phase II proof-of-concept study of spinal arthritis drugPharmaceutical Business ReviewUK-based biopharmaceutical company Izana Bioscience has commenced a pha

6 visits

Biogen's muscle drug Spinraza too costly for BritainPharmaLive (press release)Written by: Reuters Health | no-reply@reuters.com | Dated: Monday, August 13th, 2018. Biogen's pricey muscle drug

1 visits

Global Pharmacogenomics Market by Top players, Product and Production Information analysis and forecast to 2022Tactical BusinessPharmacogenomics Marketndash;Global Forecast to 2022 is a professional a

1 visits

Boston Business JournalAlnylam drug approval marks watershed moment for gene-silencing fieldBoston Business JournalJohn Maraganore, the CEO of Alnylam Pharmaceuticals Inc., stood in front of a crowd a

2 visits

Fairfield CurrentChina Biologic Products (CBPO) and Iovance Biotherapeutics ...Fairfield CurrentChina Biologic Products (NASDAQ: IOVA) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical compan

2 visits

EverythingLubbock.comHealthcast: Lowering your chances for diabetesEverythingLubbock.com"About 90 percent of the people with diabetes has type 2," Paschall explained. "If you look at type 2 diabetes,

1 visits

Motley Fool3 Top Biotech Stocks to Buy Right Now -- The Motley FoolMotley FoolOur Motley Fool contributors think now could be the perfect time for biotech investors to add Spark Therapeutics (NASDAQ:O

1 visits

Elizabethtown Hospital to host Diabetes Fair and WalkPlattsburgh Press RepublicanELIZABETHTOWN - University of Health Network, Elizabethtown Community Hospital will host a Diabetes Health Fair and Wal

1 visits